Metastatic Pancreatic Cancer - prIME Oncology
Expert Review
Expert Review

Metastatic Pancreatic Cancer

Thoughtful Selection of Treatment Across the Disease Continuum

Not a member of My prIME? Join now for instant access.

View a comprehensive review from leading experts in the field and downloadable slides on metastatic pancreatic cancer, front-line therapy and beyond. This activity features a discussion of current standard of care and guidelines, systemic treatment in the real world, and treatment sequencing for patients with metastatic pancreatic cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Aug 10, 2018

Expiration Date

Aug 10, 2019


  • Thomas Seufferlein, MD, PhD University of Ulm
    Ulm, Germany


  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Julien Taïeb, MD, PhD Georges Pompidou European Hospital
    Paris, France
  • Introduction
  • Second-line therapy for metastatic pancreatic cancer
  • Sequential therapy in metastatic pancreatic cancer
  • Treatment of metastatic pancreatic cancer in the real world
  • prIME Points™

This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers outside of United States involved in the management of patients with pancreatic cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess current and emerging treatment strategies for metastatic pancreatic cancer, including guideline recommendations, practice patterns, and new data
  • Select the most appropriate treatment sequence for patients with advanced pancreatic ductal adenocarcinoma, taking into consideration patient and disease characteristics and latest findings from clinical trials

This educational activity is supported by Servier.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Macarulla has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Seufferlein has disclosed that he has board membership with the European Society of Digestive Oncology. He has disclosed that he has received consulting fees and fees for speaking and teaching from Celgene Corporation and Shire. He has also performed contracted research for Celgene Corporation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Taïeb has disclosed that he has board membership with Shire. He has also received consulting fees from Celgene Corporation and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.